Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06905197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 70 to 140 Interventions: DZD6008 (Drug) to DZD6008 (Drug), Sunvozertinib (Drug) · Eligibility criteria expanded, about 54 words · Secondary endpoints revised (9) · 2 morev5 Show 5 more changesShow less
    • Interventions: DZD6008 (Drug) to DZD6008 (Drug), Sunvozertinib (Drug)
    • Eligibility criteria expanded, about 54 words
    • Secondary endpoints revised (9)
    • Study arms: 8 to 13
    • Study description expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 48 to 70 Eligibility criteria shortened, about 15 words · Study description shortened, about 1 wordv4 Show 2 more changesShow less
    • Eligibility criteria shortened, about 15 words
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 1 to 5v3
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2025 to May 13, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2025 to May 13, 2025
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
Trial Details
NCT Number NCT06905197
Lead Sponsor Dizal Pharmaceuticals
Conditions Non Small Cell Lung Cancer
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov